Location History:
- San Diego, CA (US) (2011)
- Media, PA (US) (2011)
Company Filing History:
Years Active: 2011
Title: Innovations in Cancer Prognosis: The Contributions of Mitch Raponi
Introduction
Mitch Raponi is a notable inventor based in San Diego, CA, who has made significant contributions to the field of cancer research. With a focus on innovative methods for predicting treatment responses and prognoses in various cancers, he holds 2 patents that reflect his dedication to improving patient outcomes.
Latest Patents
Raponi's latest patents include groundbreaking methods for determining the response of acute myeloid leukemia (AML) patients to treatment with farnesyltransferase. His research analyzed bone marrow samples from 67 patients, identifying a two-gene expression ratio (RASGRP1:APTX) that accurately predicts treatment response. This classifier has shown to improve the overall response rate by approximately 50% while maintaining a high negative predictive value (NPV), significantly enhancing patient survival rates.
Another significant patent involves a process for predicting the prognosis of squamous cell lung cancer. This method observes regulatory changes in select miRNA sequences, which can provide valuable insights into patient outcomes. The sequences analyzed include hsa-mir-146b, hsa-mir-191, and several others, indicating a comprehensive approach to understanding cancer prognosis.
Career Highlights
Mitch Raponi is currently associated with Veridex, LLC, where he continues to develop innovative solutions in cancer diagnostics and treatment. His work has been instrumental in advancing the understanding of cancer biology and improving therapeutic strategies.
Collaborations
Raponi collaborates with esteemed colleagues such as Yixin Wang and Hongtao Fan, contributing to a dynamic research environment that fosters innovation and discovery in cancer treatment.
Conclusion
Mitch Raponi's contributions to cancer research through his patents and collaborative efforts highlight the importance of innovation in improving patient care. His work exemplifies the potential of scientific advancements to transform the landscape of cancer treatment and prognosis.